The performance of companies tied to Sildenafil's past presents a intricate investment landscape. While the initial surge generated substantial gains, generic competition have significantly impacted revenue. Investing in associated pharmaceutical businesses now requires a careful assessment of patent protection , evolving healthcare trends , and th